KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables (2016 - 2025)

Historic Receivables for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $168.8 million.

  • Emergent BioSolutions' Receivables rose 2014.23% to $168.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 2014.23%. This contributed to the annual value of $174.1 million for FY2024, which is 2817.66% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Receivables is $168.8 million, which was up 2014.23% from $102.7 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Receivables high stood at $341.9 million for Q2 2023, and its period low was $102.7 million during Q2 2025.
  • Moreover, its 5-year median value for Receivables was $242.4 million (2023), whereas its average is $241.6 million.
  • Per our database at Business Quant, Emergent BioSolutions' Receivables skyrocketed by 4858.76% in 2023 and then tumbled by 6316.36% in 2025.
  • Emergent BioSolutions' Receivables (Quarter) stood at $330.5 million in 2021, then plummeted by 34.52% to $216.4 million in 2022, then increased by 12.01% to $242.4 million in 2023, then dropped by 28.18% to $174.1 million in 2024, then fell by 3.04% to $168.8 million in 2025.
  • Its last three reported values are $168.8 million in Q3 2025, $102.7 million for Q2 2025, and $234.6 million during Q1 2025.